Grant Archive - Page 55 of 138

Andras Heczey, M.D.

Funded by the Constellation Gold Network Distributors in honor of the Dick Vitale Gala

Children with liver cancers are hard to cure, if the tumor cannot be removed by surgery or has spread to distant organs. Current therapies cause significant toxicity and don’t work well against large tumors. These children need new approaches and immunotherapy may be a good solution. Immunotherapy relies on the body’s own infection and cancer fighting system.

A type of immunotherapy uses special white blood cells called T cells. T cells can be collected from patients and engineered with a molecule called chimeric antigen receptor or CAR. These CAR T cells can be infused back to patients to destroy the cancer cells.

We developed several versions of CARs which recognize glypican-3. This molecule is expressed in pediatric liver cancers. We systematically tested T cells expressing these CARs in preclinical models of liver cancer. We selected the CAR with the strongest antitumor activity. Now T cells expressing this CAR will be tested in a Phase 1 clinical trial in children.

With the help of the V Foundation, we will examine changes in the genetic programming of CAR T cells. We will evaluate the CAR T cell product, peripheral blood and biopsy samples. Our goal is to define the interaction between the CAR T cells and the tumor.

Alan Friedman, M.D.

Our body’s immune system recognizes and destroys foreign invaders such as infections or cancer. Malignant tumors try to outsmart and hide from the immune system. Therapies that activate T cells, a key part of the immune system, are effective against multiple cancers. Myeloid cells are a second important part of the immune system. Myeloid cells can be activated by removing a protein called p50. Our laboratory finds that infusion of myeloid cells lacking p50 into mice leads to shrinkage of several types of cancer, including prostate and pancreatic cancers. We now seek to further improve the effectiveness of myeloid cells lacking p50, to develop human myeloid cells lacking p50 suitable for use in patients, and to evaluate the ability human myeloid cells lacking p50 to shrink human prostate and pancreatic cancers growing in mice. We anticipate that completion of these studies will allow us to begin clinical trials testing the benefit of human myeloid cells lacking p50 as a novel treatment for multiple cancers.

James Brugarolas, M.D., Ph.D.

Immunotherapy has revolutionized cancer treatment. Immunotherapy drugs work with the immune system, which normally fights intruders such as viruses, to kill cancer cells. One approach involves taking down defenses set up by cancer cells to escape immune cells. Some tumors, such as kidney cancer, melanoma, and lung cancer, display on their surface a protein (PD-L1) that shuts off approaching killer immune cells. Drugs have been developed that mask PD-L1 allowing killer cells to dispose of cancer cells. Discoveries underlying these developments were recognized with a Nobel Prize in 2018.

However, not all tumors use the same defense mechanism. Here, we propose a novel strategy to identify patients most likely to benefit from drugs masking PD-L1. Up until now, most approaches have focused on evaluating PD-L1 on tumor biopsy samples. However, only one cancer site is sampled, few cells are evaluated, and the results are often unreliable.

We have developed a strategy adapting a radiology test, positron emission tomography (PET), and a PD-L1 masking drug, that allows us to evaluate PD-L1 across all tumor sites. In preliminary experiments, we show that we can label a PD-L1 masking drug so that it can be detected by PET. We then show, using patient tumors transplanted into mice, that we can identify tumors with high PD-L1.

Our goal is to evaluate immuno-PET (iPET) in patients in a clinical trial. If successful, iPET will better match patients to their immunotherapy drug, and identify patients unlikely to benefit and for whom other strategies should be developed.

Yanis Boumber, M.D., Ph.D.

Funded by the Stuart Scott Memorial Cancer Research Fund

Lung cancer is the main cause of death in the world. For unknown reasons, African Americans (AA) have more aggressive lung cancer compared to Caucasians. Recently, immunotherapy demonstrated that one out of five of patents have tumor shrinkage. Long term remissions are happening in one out of seven lung cancer patients. This is very exciting, but combinations of 2 or 3 immunotherapy drugs are needed to cure more patients.

We proposed the lung cancer treatment combination that can block tumor blood vessel growth, and boost immune system. We think that this combination approach will cure more lung cancers. We will soon start a clinical study combining two immunotherapy drugs. One out of four patients on our study will be AA. We hope to find immune or blood vessel growth related markers to help predict who would benefit from this drug combination. This can help to use the right drugs for the right patients. In this study, we also plan to investigate why AA have more aggressive lung cancer.

In Aim 1, we will perform detailed analysis of blood proteins and white cells from the blood of patients participating in our study. In Aim 2, we will correlate genes and other markers with response to immunotherapy combination. In Aim 3, we will compare blood proteins and tissue gene levels between AA and Caucasians.

Nabeel Bardeesy, Ph.D.

Intrahepatic cholangiocarcinoma (ICC) is the second most common kind of liver cancer. It is a very difficult disease to treat. Only about one out of ten patients live more than five years after the cancer has been detected. There are several different types of ICC. One important type has changes in a gene called the Fibroblast Growth Factor Receptor 2 (FGFR2). Drugs that turn off FGFR2 cause the tumors to shrink, but the tumors eventually become resistant to the drug and begin to grow again. The goals of this project are to understand what causes drug resistance and to develop ways to prevent it from happening. In this project, we will study samples of tumors from patients who are being treated with drugs against FGFR2. We will also make models that allow us to study ICC in the laboratory. Finally, we will use a method that could allow us to create a new kind of drug that is better at turning off FGFR2. We hope that our work will result in new treatments that help patients with ICC to live longer.

Carey Anders, M.D. & Ben Vincent, M.D.

First year of this Vintner Grant funded by the 2018 V Foundation Wine Celebration in honor of Robin Lail

Triple negative breast cancer (TNBC) is breast cancer that lacks HER2 and ER/PR receptors. Because most treatments are based on having these markers, TNBC is hard to treat. Additionally, TNBC often spreads to the brain (brain metastasis), which is even harder to treat. Radiation therapy (RT) is a standard local therapy for TNBC brain metastases; however, survival is less than 6 months.

Immune cells (found throughout the body) fight invaders like viruses, bacteria and cancer. However, cancer cells are highly adept at hiding from immune cells. Immunotherapies are being tested to help immune cells fight cancer better. There have been promising results using immunotherapies to treat brain metastases. We have shown that TNBC brain metastases have a higher number of immune cells called tumor infiltrating lymphocytes (TILs) compared to TNBC in breasts. More importantly, we found that patients with a higher number of TILs in their brain metastases live longer. Adding RT to immunotherapies can help immune cells to fight cancer. We will use mouse models to test this strategy, which will lead to a clinical trial in humans. We expect immunotherapy will also treat cancer inside and outside of the brain at the same time, which will improve the lives of patients facing this disease. We also want to find more signals in brain metastases (biomarkers) that will guide selection of the right immunotherapy for each patient. New biomarkers will help us treat the right patient, at the right time, in the right way, with immunotherapies.

Jessie Villanueva, Ph.D.

The V Foundation MRA Young Investigator Award

Co-funded with The Melanoma Research Alliance

Although significant progress has been made treating melanoma and the recent approval of several drugs for the treatment of advanced disease, several challenges remain.  For example, clinical responses are generally short-lived as tumors quickly become drug resistant and patients relapse. Moreover, tumors can develop drug resistance through a diverse number of molecular mechanisms, making the development of second-line therapies extremely daunting.  Therefore, it is critical to identify therapeutic targets that are common to the majority of resistant tumors.  We have recently found that a protein kinase called S6K is activated in melanomas resistant to BRAF and MEK inhibitors.  Moreover, we showed that inhibition of this protein using a triple drug combination blocked the growth of resistant tumors.  This provides strong rationale for establishing S6K as a novel target for melanoma therapy.  Notably, S6K is a common node for most resistance pathways.  We propose to investigate the role of S6K in melanoma and determine the therapeutic value of targeting this protein.  Towards these goals we will determine the consequences of blocking S6K in melanoma, identify the proteins that are regulated by S6K and use this knowledge to delineate combinatorial approaches that can lead to long-term tumor remission in a large number of melanomas, including those resistant to BRAF and MEK inhibitors.  We expect that the data generated by these studies can be quickly translated into new strategies aimed at maximizing the therapeutic efficacy of MAPK inhibitors in melanoma and provide actionable information that will guide the design of future clinical trials.

Judy Villablanca, M.D.

Co-funded with Carousel of Possible Dreams/Friends of Cathryn and the Dick Vitale Gala

Only 45% of children with high-risk neuroblastoma are cured.  The New Approaches to Neuroblastoma Therapy (NANT) consortium links laboratory and clinical investigators to develop therapies with high potential for improving survival and performs the first testing of them at 13 neuroblastoma centers.  We propose new clinical trials for patients with resistant or recurrent disease that aim to 1) improve immunotherapy; 2) improve chemotherapy by targeting key drivers of the disease; and 3) improve measurement of response and prediction of outcome with a “biomarker” test for blood and bone marrow.  We anticipate that these innovative studies will improve survival for children with high risk neuroblastoma.

Pepper Schedin, Ph.D.

Funded by the Kay Yow Cancer Fund

A growing body of scientific evidence suggests that up to half of all young women’s breast cancers are related to a recent pregnancy. Approximately 12,000-15,000 young mothers each year in the U.S. and 180,000 women worldwide will be diagnosed with breast cancer within 5 years of childbirth, demonstrating that young mother’s with breast cancer is a global problem. Our lab found that this population has a three-fold increase in metastasis and death, and we traced the increased death to the inflammatory effects of breast tissue “remodeling” following pregnancy –the time when breast tissue is removed to phase out of the job of lactation. Using rodent models of postpartum breast cancer, we found that ibuprofen treatment given for only 10 days after weaning blocks the development of postpartum breast cancers. Studies supported by the Kay Yow Cancer Fund permitted us to use our mouse models to determine whether ibuprofen can be used to prevent postpartum breast cancer, as well as let us investigate whether ibuprofen can be used to help treat young women already diagnosed with postpartum breast cancer. Our goal is to determine if a relatively low-cost intervention, such as ibuprofen or aspirin, can be readily incorporated into current treatment regimens to prevent the occurrence and/or progression of young women’s breast cancer. Results from this Kay Yow Cancer Fund grant confirm that the window of time following weaning is unique, characterized by tissue remodeling that is driven by the same protein that drugs like aspirin and ibuprofen inhibit. We anticipate that aspirin and ibuprofen, when combined with standard of care treatments for breast cancer, will reduce mortality in young women diagnosed with postpartum breast cancer. Further, our mouse studies identify why ibuprofen prevents progression of postpartum breast. We find that postpartum breast cancers are infiltrated with high levels of “bad” immune cells that block the ability of “good” immune cells to attach the cancer. We find that ibuprofen specifically blocks these “bad” immune cells and activates the “good” immune cells, permitting tumor destruction. In future studies, we will confirm that ibuprofen and drugs similar to ibuprofen activate the “good” arm of the immune system in postpartum women, as we see in mice, and we will conduct the first clinical trial designed to fight postpartum breast cancer.  

Damon Reed, M.D.

Funded by the Dick Vitale Gala

There are over 170 FDA approved chemotherapeutic medications.  These medications have shown benefit to a particular segment of cancer populations, often multiple groups of patients.  Because of the rarity of pediatric cancers, very few of the medications that are used to improve the lives of children with cancer are FDA approved for that specific use, so called off-label use.  Incorporating new medications into childhood cancer treatment often involves testing one agent at a time across a variety of diagnoses followed by focusing on a subset or a few types of cancer.  This process has been slow to identify new agents in a group of tumors known as sarcomas.  Recently, there have been a significant number of medications approved and it would be impossible to test them all on patients in the manner described above. Furthermore, studies in models of sarcomas have not always been reliable predictors of the medications because they have been tested in amounts that are not achievable in humans or for durations that cannot be achieved without unacceptable side effects.  We propose looking at many FDA approved agents at levels that can be safely achieved in people across a panel of sarcoma models to identify agents and then combinations of agents that can be rapidly incorporated into a disease specific trial.  We aim to test these agents, and, in the coming two years, identify promising combinations in the four most common sarcomas: osteosarcoma, Ewing Sarcoma, alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma.